Successful beta trial with NK Care

January 2025:

Ediphor is pleased to announce the successful completion of its beta trial for the Ediphor diagnostic platform, conducted by NK Care in Denmark.

As a leader in home care services, NK Care recognizes the myriad of benefits that the Ediphor diagnostic platform brings to the table. NK Care’s patients, often vulnerable to respiratory diseases, have unique needs that demand innovative solutions. With many patients being less mobile, the option for highly accurate, digitally conneted, home testing is invaluable.

The impact of common respiratory illnesses, such as the flu, can be serious and even life-threatening for the Home Care industry’s patient population. That’s why the Ediphor device, with its low cost, high accuracy, and ease of use, stands out as an essential tool for home care and elderly care businesses.

Claus Jensen, CEO at NK Care, commented:

“The Ediphor diagnostic platform not only enhances patient safety but also empowers our caregivers. This technology will protect our patient population, with the current URI assays. As the Ediphor assay portfolio expands, we will be able to provide even greater levels of service across other indications that impact our customers."